145 related articles for article (PubMed ID: 29940115)
21. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
22. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
23. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
24. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Goh KC; Novotny-Diermayr V; Hart S; Ong LC; Loh YK; Cheong A; Tan YC; Hu C; Jayaraman R; William AD; Sun ET; Dymock BW; Ong KH; Ethirajulu K; Burrows F; Wood JM
Leukemia; 2012 Feb; 26(2):236-43. PubMed ID: 21860433
[TBL] [Abstract][Full Text] [Related]
25. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
Cao H; Cheng Y; You L; Qian J; Qian W
Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
[TBL] [Abstract][Full Text] [Related]
26. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
[TBL] [Abstract][Full Text] [Related]
27. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Wang F; Zhong BW; Zhao ZR
J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
[TBL] [Abstract][Full Text] [Related]
28. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
Ning CQ; Lu C; Hu L; Bi YJ; Yao L; He YJ; Liu LF; Liu XY; Yu NF
Eur J Med Chem; 2015 May; 95():104-15. PubMed ID: 25800646
[TBL] [Abstract][Full Text] [Related]
29. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Zhang K; Huang R; Ji M; Lin S; Lai F; Wu D; Tian H; Bi J; Peng S; Hu J; Sheng L; Li Y; Chen X; Xu H
Eur J Med Chem; 2024 Jan; 264():116015. PubMed ID: 38048697
[TBL] [Abstract][Full Text] [Related]
30. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
Hackanson B; Rimmele L; Benkißer M; Abdelkarim M; Fliegauf M; Jung M; Lübbert M
Leuk Res; 2012 Aug; 36(8):1055-62. PubMed ID: 22464548
[TBL] [Abstract][Full Text] [Related]
31. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
Qiu Q; Chi F; Zhou D; Xie Z; Liu Y; Wu H; Yin Z; Shi W; Qian H
J Med Chem; 2023 Apr; 66(8):5753-5773. PubMed ID: 37057760
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
[TBL] [Abstract][Full Text] [Related]
33. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
Wang XN; Wang KY; Zhang XS; Yang C; Li XY
Biochem Biophys Res Commun; 2018 Oct; 504(4):812-819. PubMed ID: 30217455
[TBL] [Abstract][Full Text] [Related]
34. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
35. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
36. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
37. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors for enhancing activity of antifungal agent: a patent evaluation of WO2014041424(A1).
Zhang L; Xu W
Expert Opin Ther Pat; 2015 Feb; 25(2):237-40. PubMed ID: 25381141
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of histone deacetylase 6 in inflammatory diseases.
Ran J; Zhou J
Thorac Cancer; 2019 Mar; 10(3):405-412. PubMed ID: 30666796
[TBL] [Abstract][Full Text] [Related]
40. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]